Could a neuroprotective retinal therapy be delivered as an eye drop rather than an injection? A new Cell Death & Disease study suggests that may be possible – at least preclinically. Investigators report that topical administration of JGRi1, a peptide designed to disrupt the interaction between JNK2 and syntaxin-1A (STX1A), reached the mouse retina and mitigated degeneration in two experimental models of retinal injury.
The biological rationale is noteworthy. Rather than broadly blocking NMDA receptors – a strategy that has repeatedly disappointed in translation – the authors targeted a downstream presynaptic mechanism they describe as a “non-canonical presynaptic-induced glutamate spillover” loop, or nPING. In this model, glutamate overstimulation activates presynaptic NMDA signalling, triggering JNK2-dependent phosphorylation of STX1A, enhancing SNARE complex assembly and further glutamate release.
Before testing efficacy, the group first asked a practical question: can the peptide actually penetrate the eye from the surface? Using fluorescein-tagged JGRi1, they showed dose-dependent retinal accumulation after topical dosing, particularly in the ganglion cell layer (GCL) and outer plexiform layer. The study’s permeability findings suggest that the Tat-linked peptide, but not the non-permeable control, successfully reached retinal tissue following eye-drop administration.
The peptide was then evaluated in two models: an ex vivo optic nerve cut model and an intravitreal NMDA injury model. In both systems, degeneration was accompanied by retinal ganglion cell loss, increased cleaved caspase-3, elevated glutamate immunoreactivity, and increased JNK2/STX1A expression. In the ex vivo axotomy model, topical JGRi1 preserved RGC survival, reduced apoptosis, lowered glutamate levels, decreased JNK phosphorylation and STX1A phosphorylation, and reduced SNARE complex formation. The rescue was visible across histology, immunofluorescence, and immunoblot readouts, with the scrambled control peptide consistently failing to reproduce the effect.
The in vivo NMDA model produced a similar signal. JGRi1 improved RGC survival, preserved cholera toxin B uptake and transport as a marker of axonal integrity, reduced retinal glutamate accumulation, and decreased JNK2–STX1A interaction as measured both by colocalization analysis and proximity ligation assay. The study data also suggest a reduction in IBA1-positive microglial infiltration, raising the possibility that the compound modulates inflammatory as well as excitotoxic consequences of retinal injury.
There are important caveats. This is an animal study, and the models are acute rather than chronic. No randomization or blinding were performed, and the work does not address long-term functional vision outcomes, pharmacokinetics in human eyes, or formulation challenges for clinical use. Still, the translational proposition is compelling: a topically delivered peptide that targets a specific excitotoxic protein–protein interaction without altering baseline retinal glutamate physiology.
The broader significance lies in the mechanism of this therapy. JGRi1 is not simply another anti-excitotoxic agent; it represents a more selective attempt to shut down pathogenic glutamate amplification at its presynaptic source. If that concept survives further validation, it could open a new therapeutic avenue not only for glaucoma and optic neuropathies, but potentially for a wider range of retinal neurodegenerative disease.
